Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SUPN message board posts where the ticker symbol SUPN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest SUPN SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 5.02
Acc-no: 0001104659-18-034093 (34 Act)  Size: 20 KB
2018-05-17 001-35518
18843415
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-033849 Size: 14 KB
2018-05-16
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-032900 Size: 25 KB
2018-05-14
8-K  Documents Current report, items 5.02 and 9.01
Acc-no: 0001104659-18-032502 (34 Act)  Size: 71 KB
2018-05-11 001-35518
18826593
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001104659-18-032082 (34 Act)  Size: 5 MB
2018-05-10 001-35518
18821678
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-031376 (34 Act)  Size: 216 KB
2018-05-08 001-35518
18815794
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001047469-18-003310 (34 Act)  Size: 873 KB
2018-04-27 001-35518
18785681
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-18-026631 (34 Act)  Size: 47 KB
2018-04-25 001-35518
18774762
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-025639 Size: 18 KB
2018-04-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-18-023012 Size: 19 KB
2018-04-09
More SUPN SEC Filings


Related news from
Mon, 21 May 2018
18:00:12 +0000
Analyzing BEAT, SUPN, ADBE And RHT Stocks
BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market cap had gained 373% between 2013 and 2017.
Mon, 21 May 2018
14:59:25 +0000
Total Returns and Sector Exposure for Growth Indexes
If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT). The S&P 500 Growth index generated a three-year and five-year annualized return of 13.2% and 15.2%, respectively. These returns compare to the S&P 500 (SPY) at 10.7% and 13% for the same timespan, respectively. The S&P 500 Growth index generated YTD (year-to-date) return of 5.5%, compared to the S&P 500 at 1.5%. The S&P 500 Growth has 41% exposure to information technology, compared to the S&P 500 at 24.8%. ...
Wed, 16 May 2018
15:10:46 +0000
Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone
Leading biotech stock and IBD 50 member Ligand Pharmaceuticals is in a buy zone after reporting 172% earnings growth.
Tue, 15 May 2018
12:51:12 +0000
Implied Volatility Surging for Supernus (SUPN) Stock Options
Supernus (SUPN) needs investors to pay close attention to the stock based on moves in the options market lately.
Mon, 14 May 2018
12:00:00 +0000
Today’s Research Reports on Stocks to Watch: Intrexon and Supernus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / May 14, 2018 / While one biotech company went up, the other went down on Friday. Intrexon shares tanked on Friday over first quarter results that didn’t impress traders, as shares of Supernus Pharmaceuticals were galloping ahead on a strong first quarter report. Intrexon Corporation shares closed down almost 20% on Friday with a little over 5 million shares traded.
Fri, 11 May 2018
19:02:11 +0000
6 Ways To Play Biotechs As Small Stocks Score Big Gains
The biotech group is trying to climb past its 50-day moving average, so it may be a good time to keep an eye on biotech ETFs.
Fri, 11 May 2018
07:56:42 +0000
Edited Transcript of SUPN earnings conference call or presentation 9-May-18 1:00pm GMT
Q1 2018 Supernus Pharmaceuticals Inc Earnings Call
Tue, 08 May 2018
22:15:52 +0000
Supernus: 1Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had net income of 49 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Tue, 08 May 2018
20:40:32 +0000
Supernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue
Total revenue of $90.4 million, a 57% increase over 2017 Net product sales of $89.1 million, a 58% increase over 2017 Operating earnings of $31.4 million, an 87% increase over 2017 Diluted earnings per ...
Tue, 24 Apr 2018
20:15:00 +0000
Supernus to Host First Quarter 2018 Earnings Conference Call
ROCKVILLE, Md., April 24, 2018-- Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, ...
Sat, 21 Apr 2018
11:16:00 +0000
3 Top Biotech Stocks to Buy Right Now
There's good reason to consider buying shares in these biotech companies soon.
Thu, 19 Apr 2018
15:55:54 +0000
Harry Boxer’s biotech-stock breakouts to watch
In focus: uniQure, Supernus Pharmaceuticals and ViewRay.
Wed, 18 Apr 2018
13:01:16 +0000
Analysts’ Recommendations for AbbVie in April 2018
In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.
Mon, 16 Apr 2018
12:05:46 +0000
See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding SUPN totaled $776 million.
Thu, 12 Apr 2018
16:02:11 +0000
Top 3 Growth Stocks For The Month
Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...
Wed, 11 Apr 2018
11:45:00 +0000
Factors of Influence in 2018, Key Indicators and Opportunity within Harmonic, Supernus Pharmaceuticals, America First Multifamily Investors, Ballard Power, ServiceSource International, and Materialise NV — New Research Emphasizes Economic Growth
NEW YORK, April 11, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Mon, 09 Apr 2018
17:00:18 +0000
Here’s What Drove Supernus Pharmaceuticals Stock in March 2018
Supernus Pharmaceuticals (SUPN) stock has risen 18.2%, from $38.75 on March 1, 2018, to $45.80 on March 29, 2018. In its 2017 results announced on February 28, 2018, the company focused on developing and commercializing drugs targeted at treating central nervous system diseases. It reported a 41% year-over-year (or YoY) growth in fiscal 2017 revenues, which were about $300 million. It also reported earnings before income tax of around $100 million in 2017, which is a YoY rise of 100%. ...
Fri, 30 Mar 2018
05:26:08 +0000
Edited Transcript of SUPN earnings conference call or presentation 28-Feb-18 2:00pm GMT
Q4 2017 Supernus Pharmaceuticals Inc Earnings Call
Thu, 15 Mar 2018
16:07:23 +0000
Supernus getting Maryland incentives in HQ relocation, plans to add 160 jobs
Now we know Maryland is helping out to the tune of more than $1.7 million. Maryland Gov. Larry Hogan announced Wednesday the state will provide $800,000 loan through the Maryland Economic Development Assistance Authority and Fund to assist with the move. Montgomery County is providing a $500,000 conditional grant through its Economic Development Fund, and Gaithersburg is providing a grant up to $400,000 through its Economic Development Opportunity Fund.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum is comprised of a large and growing, diverse, knowledgeable group of investors. The attribute you should appreciate that this wonderful group makes available to you as an incoming member is Generosity. Research, firsthand sector sophistication, source references and sometimes remarkably insightful analyses are given freely by the members so you may do your own due dilligence in making informed investment decisions." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards